


PIQ



# Proteomics International

LABORATORIES LTD

## Investor Presentation

26<sup>th</sup> August 2020

ASX: PIQ

BUILDING A GLOBAL  
DIAGNOSTICS BUSINESS

# DISCLAIMER



ASX:PIQ

This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake its own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

# CORPORATE OVERVIEW



ASX:PIQ

**Proteomics International Laboratories Ltd (ASX: PIQ) is a medical technology company at the forefront of predictive diagnostics and bioanalytical services**

## DIAGNOSTICS

### PromarkerD


- Predictive test for early identification of diabetic kidney disease (DKD)
- Accurately predicts four years prior to typical clinical diagnosis
- Patented, cost-effective, easy to use technology
- Early diagnosis can delay disease onset, resulting in significant benefits to the patient and healthcare systems
- Additional tests in the pipeline – Endometriosis, COVID-19, Gastro, Oxidative Stress, Asthma & Lung Disease

## BIOANALYTICAL SERVICES

- Strong demand from industry for these specialised analytics
- Year on year revenue growth
- Enhanced capabilities with >\$4m invested in cutting-edge facility
- Revenue offsets the cash burn from R&D and product development

## CORPORATE SNAPSHOT – 25/8/2020

ASX code	PIQ
Share Price	\$0.605
Shares on issue (+ 4m options)	92m
Market Capitalisation	\$55.6m
Enterprise Value	\$52m
Cash	\$2.4m (+\$1.2m R&D tax)
Cash Runway	> 12 months
Revenue & other income – FY19	\$2.7m
Directors Shareholding	25%






ASX:PIQ

# PROMARKER – PLATFORM TECHNOLOGY



Promarker™ is a platform technology that can identify unique protein biomarkers ‘fingerprints’



The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics to formulate commercial diagnostic tests

# PromarkerD



**PREDICTIVE TEST FOR DIABETIC KIDNEY DISEASE**

# BUILDING A GLOBAL DIAGNOSTICS BUSINESS



ASX:PIQ

**PromarkerD is revenue ready and Proteomics International is currently in discussions globally to bring the test to market**

**Simple Technology Platform**  
PromarkerD Immunoassay ready



Certified laboratories can easily introduce the PromarkerD immunoassay as an LDT

**High Statistical Performance**



Peer reviewed publications - Analytical & Clinical validity evidence

**Regulatory Approval in Europe**



CE Mark registration received for the PromarkerD Immunoassay

**Big Pharma Interested**



Collaboration with Janssen - global multi-centre clinical study

**Enormous Market**



463m adults have diabetes globally - 1 in 3 currently have DKD

**Therapeutic Treatments Available**




SGLT2 inhibitor class drugs with renal protection approved for type 2 diabetes treatment

**Reimbursement**

Engaged industry leading consultant to obtain a unique US reimbursement code

# MARKET SIZE?

- Global IVD market worth US\$67 billion in 2019, projected to reach \$91 billion by 2027
- Proteomics market valued at US\$24 billion in 2017, expected to reach \$72 billion by 2025 at CAGR of 14.5%
- Driven by developments in personalized medicine and identification of biomarkers for disease diagnosis







ASX:PIQ

# A MAJOR OPPORTUNITY

## THE PROBLEM

- ▶ 463 million people have diabetes
  - ▶ 1 in 3 diabetic adults currently have chronic kidney disease
- ▶ There are no early symptoms of diabetic kidney disease - **Kidney function can fall below 15-20% with no symptoms**
  - ▶ The current standard-of-care tests cannot predict the onset of diabetic kidney disease
  - ▶ Diabetic kidney disease leads to end stage renal disease (ESRD) which requires dialysis (US\$72,000 p.a.) or kidney transplant
  - ▶ **Total cost of diabetic kidney disease = US\$50 billion per year in USA alone**



## THE SOLUTION

PromarkerD: A predictive test for diabetic kidney disease

- ▶ PromarkerD can **predict** the onset of disease **before** clinical symptoms appear
- ▶ ***Doctors can then prescribe an early therapeutic treatment to slow or stop the onset of disease***



# PromarkerD PLATFORMS



ASX:PIQ

## PREDICTIVE TEST for DIABETIC KIDNEY DISEASE

PromarkerD assay can be readily ported to different pathology lab platforms



Immunoassay Kit



Laboratory Developed Test - LDT



Automated Immunoassay


- **Cost-effective, easy-to-use** technology platforms
- **Regulatory approval** – European CE Mark registered
- In commercial discussions with **pathology laboratories, diagnostics manufacturers, and pharmaceutical companies**

# PromarkerD IN THE CLINIC



ASX:PIQ

## TEST RESULTS



## Result Interpretation

Low Risk	Standard diabetes management; Status tested annually.
Moderate Risk	More frequent monitoring; Optimisation of lifestyle factors; Review of glycemic targets and management; Review of non-glycemic risk factors and their management including blood pressure and lipids; Avoidance of potentially nephrotoxic drugs; Utilisation of therapeutic drugs with evidence of renoprotection; Status tested every 3-6 months.
High Risk	Very close monitoring; Intensive management strategies based on those for 'Moderate risk' above with optimisation of treatments for diabetes and other risk factors. Status tested every 3 months.

Interpretation of Risk Scores (based on recommendations from the ADA DKD Consensus report)

## PREDICTIVE TEST for DIABETIC KIDNEY DISEASE

PromarkerD patient reports use a traffic light scoring system for optimal performance

A simple blood test that measures three plasma proteins combined with three clinical factors (age, cholesterol, eGFR)

In published clinical studies PromarkerD predicted 86% of otherwise healthy diabetics who went on to develop kidney disease within 4 years



ASX:PIQ

# TREATMENTS FOR DKD - SGLT2 INHIBITORS

## The GLIFLOZINS

- SGLT2 inhibitors, known as Gliflozins, treat diabetes by helping the kidneys to lower blood glucose levels
- Empagliflozin (Lily & Boehringer Ingelheim), Dapagliflozin (Astra Zeneca & Bristol-Myers Squibb), and Canagliflozin (Janssen) are class leading approved diabetes treatments
- 30 September 2019, Canagliflozin (Invokana™) became the first drug in 20 years to be approved for the treatment diabetic kidney disease
- The gliflozins all appear to exhibit renal-protective properties and able to reduce the risk of renal failure, dialysis or kidney transplantation for DKD patients
- 2019 drug sales for:
  - **Empagliflozin (Jardiance™) - Est >US\$3 billion\***
  - **Dapagliflozin (Farxiga™) - US\$1.54 billion\***
  - **Canagliflozin (Invokana™) - US\$735 million\***

## COMMERCIAL UPSIDE

- **PromarkerD could become a prognostic test for big pharma companies that are:**
  - promoting an approved treatment - a complementary diagnostic (CDx) will guide patients to their treatment
  - conducting clinical trials - patient populations can be targeted/recruited to enhance overall efficacy (reduce placebo or negative response)
- Potential to capture at risk patients up to 4 years earlier
- Earlier treatment, could mean lower drug doses with lower side-effects and improved drug safety profile, and improved patient outcomes
- Upcoming FDA regulatory approval process should be accelerated by using the Janssen/PromarkerD data

\*<https://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/>

\*<https://www.fiercepharma.com/pharma/invokana-win-kidney-patients-could-help-j-j-right-sglt2-ship>



Proteomics International and Janssen are studying the performance of PromarkerD in predicting decline in kidney function and treatment response in patients from a Janssen completed clinical trial

## STAGE 1 STUDY

### ► **PromarkerD validated in global multi-centre study of 3,000 people**

- Results co-presented at the 80<sup>th</sup> Scientific Sessions of the American Diabetes Association (ADA), 13 June '20
- PromarkerD predicted outcomes in the CANVAS trial (CANagliflozin CardioVascular Assessment Study)
- The results showed that patients predicted by PromarkerD to be at high-risk of chronic kidney disease were 13.5 times more likely than the low-risk group to develop the disease, with the results showing high statistical significance ( $P = 1.3 \times 10^{-104}$ )
- The PromarkerD statistics compare favourably against diagnostic & prognostic tests already on the market for other chronic diseases

## COLLABORATION EXPANDED TO STAGE 2

- Janssen elected to expand the collaboration in March 2020
- Stage 2 study to determine if PromarkerD can help assess the effectiveness of canagliflozin as a treatment for diabetic kidney disease
- The additional stages to be completed later in CY2020 & subject to peer review before release
- **Potential for PromarkerD to become a Complementary Diagnostic (CDx) means a PromarkerD test could be used:**
  - upon prescription of drug treatments for diabetes
  - throughout a patient's course of treatment (potentially lifetime) to monitor the ongoing risk of developing chronic kidney disease


# ROUTE TO MARKET



ASX:PIQ


## LABORATORY DEVELOPED TEST (LDT)

- **Immunoassay or Mass spectrometry**
- Tests run via certified laboratories
- The LDT permits fast adoption of a new test in advanced markets
  - **Fast regulatory pathway**
  - **Builds market demand**



## IN VITRO DIAGNOSTIC TEST (IVD)

- Immunoassay **kit** or **automated machine platform**
  - both platforms standard to pathology laboratories
- Assay validated
- CE Mark approved
- 
- **- Ready to commercialise**



## Example of out-licensing model for a Pathology Laboratory

- PIQ licences test to be run in certified lab via Immunoassay (e.g. US) or Kit (e.g. EU)
- PIQ facilitates the production and delivery of reagents to laboratory
- Lab conducts tests using reagents and sends results (raw data) to the PromarkerD hub (server)
- PromarkerD algorithm calculates risk score (Low, Moderate, High) and returns report to lab
- Lab pays PIQ a royalty (5-15%) per test





ASX:PIQ

# MARKET OPPORTUNITY – PromarkerD

## Market assumptions:

- **Test is performed once per year per patient on average** [Standard of care: High-risk patients are tested every 3-6 months; Low-risk every 2 years].
- **Test price of US\$55-\$150** [\$55 is based on use of existing CPT codes for similar analytes to the PromarkerD panel; \$150 is based on stakeholder engagement responses (market access study conducted by independent consultant)].
- **Standard industry royalty rates range from 5-15%**

Country	Patent/ Application No.	Status	Diabetes Prevalence <sup>1</sup>
Australia <sup>2</sup>	2011305050	Granted	1,288,300
Brazil	BR1120130067640	Granting	16,780,800
Canada	2811654	Granted	2,793,500
China	ZL201180053583.9	Granted	116,446,900
Europe <sup>2,3</sup>	3151012	Granted	59,322,100
Hong Kong	18115912.3	Pending	723,400
India	3012/DELNP/2013	Pending	77,005,600
Indonesia	W00 2013 01585	Granted	10,681,400
Japan	2013-528474	Granted	7,390,500
Russia	2596486	Granted	8,288,500
Singapore	188527	Granted	640,400
USA <sup>2,4</sup>	US 9,146,243	Granted	30,987,900
			<b>332,349,300 Total</b>

<sup>1</sup> International Diabetes Federation (IDF) Atlas 9th Edition 2019 [Age group 20-79 years; Total = Diagnosed (48.7%) + Undiagnosed (51.3%)].

<sup>2</sup> Australia, Europe, USA patent extended to cover use of the test for any form of kidney disease (NB Further studies are required to prove efficacy of PromarkerD for applications beyond DKD)

<sup>3</sup> Covers France, Germany, Italy, Spain, Turkey, and the United Kingdom, which cumulatively have 29.6 million adults with diabetes.

<sup>4</sup> USA patent further extended to cover method for identifying drugs for abnormal kidney function using one of the PromarkerD biomarkers (CD5L).

# DIAGNOSTICS PIPELINE

The Promarker™ research pipeline and typical timeline is:

- Ethics & gov approval (3 months)
- Discovery (3-6 months),
- Proof of concept (6 months)
- Clinical studies (12 months)

## FURTHER GLOBAL POTENTIAL IN NEW MARKETS

- ▶ Proteomics endeavours to leverage its Promarker™ Platform to develop and commercialise a suite of diagnostic tests
- ▶ Potential for faster market adoption for a new diagnostic test, post a successful PromarkerD commercialisation
- ▶ Enormous markets and revenue potential

### DIAGNOSTICS RESEARCH AND DEVELOPMENT – THE PROMARKER™ PIPELINE





# ENDOMETRIOSIS



ASX:PIQ

## WHAT IS ENDOMETRIOSIS?

- ▶ A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines)
- ▶ The most common symptoms are chronic pain and menstrual irregularities
- ▶ Diagnosis typically takes 7 to 12 years due to the lack of a diagnostic tool beyond invasive surgery = **Significant unmet medical need**
- ▶ **Affects 1 in 9 women and costs Australia over AU\$10 billion a year – Global opportunity significantly higher**

## Promarker™ for Endometriosis

- ▶ Newly identified biomarkers via the Promarker™ platform provide breakthrough in the effort to create a world-first test standard blood sample test for endometriosis
- ▶ Proof of concept study performed on 54 women returned statistically significant results
- ▶ Patent filed for new invention



# COVID-19 DIAGNOSTICS & OXIDATIVE STRESS

## COVID-19 DIAGNOSTICS

- **Develop a rapid diagnostic test for the identification of the SARS-CoV-2 virus**
  - Half of people tested positive for SARS-CoV-2 were reported as having no symptoms
  - Asymptomatic cases are the real and present risk of significant undetected community transmission of COVID-19
- **Develop a diagnostic test to determine why some people are more severely affected than others**
  - Involve isolating biomarkers that give insights into the progression of the COVID-19 disease
  - Predict which patients are at greatest risk of requiring significant medical intervention
  - Aim to improve triaging at hospitals when patients present with COVID-19

## OXIDATIVE STRESS (2-TAG)

- The patented technology called "2-tag" measures the oxidative stress in a system (i.e. body of human or animal)
- High levels of oxidative stress can be dangerous and have been linked to a wide range of chronic diseases including stroke, heart attack, Parkinson's disease, and muscular dystrophy and muscle damage
- Collaboration with the University of Western Australia to develop methodology that could become the next generation of medical diagnostic tests
- The 2-tag test demonstrated proof of concept with several publications targeting Duchenne muscular dystrophy
- **Global opportunity in human health, elite sport's health and animal health (e.g. Horse racing industry)**



## Proteomics International state-of-the-art biomarker analysis facilities



- World leading facility in Western Australia – Public Private Partnership co-investing >\$4m including from Federal and State Government agencies
- Best in class Quality Control testing
- Biosimilars & biologics - Assisting pharmaceutical companies develop generic drugs
- Food quality (e.g. milk)
- Pharmacokinetic (PK) testing for clinical trials
- World's first company to receive ISO 17025 Laboratory Accreditation for proteomics services (protein testing)
- **YoY Revenue growth**



# MILESTONES & UPCOMING CATALYSTS

## EXCEPTIONAL GLOBAL OPPORTUNITY

- ✓ **Proven diagnostics business with global potential**
- ✓ **Scalable licensing model with high margins and low rollout cost**
- ✓ **Minimal burn rate ensures rollout is funded**
  - Established revenue reduces burn, trending to cash flow positive
- ✓ **Strong IP position**
  - Patents granted in major jurisdictions for ground-breaking PromarkerD predictive test
- ✓ **Cutting-edge technology & proven platform - pipeline of potential globally significant tests**
  - Proof of concept established with PromarkerD: endometriosis and gastro undergoing pre-clinical work
- ✓ **World leading technology in an area of significant unmet medical need**

## SHARE PRICE CATALYSTS 2020-21

### PromarkerD

- **Results from Janssen studies – Stage 2**
  - diagnostic capability to assist drug developers to market kidney disease treatments
- **Further licencing deals in major territories**
  - diagnostics, pharmaceuticals, service providers
- Regulatory approvals – ISO 13485, FDA
- Reimbursement (Medicare) code in the USA
- Patents in other global jurisdictions

### Analytical services






- New contracts for protein QC, biosimilars & PK testing

### Diagnostic test development

- Endometriosis, gastro, COVID-19, asthma and lung disease
- Expansion into other chronic diseases & applications



# APPENDICES - PEER COMPARISON

	Stock Code	Company Focus	Market Capitalisation	Share Price	FY19 Revenue	FY19 Net Profit/Loss	Addressable Market(s) US\$Bn
 <b>Renalytix AI</b>	RENX.LSE RNLX.US	DKD test based on AI and a combination of predictive blood-based biomarkers, genetic factors and electronic health records. Expensive (US\$950 per test), non-mass market.	<b>£407m + US\$81m (~A\$852.5m)</b>	565p & US\$14.72	N/A	£6.9m (A\$12.6m) loss	US\$9.5Bn
 <b>Volpara Health Technologies</b>	VHT.ASX	SAAS Diagnostic technology that utilises AI to improve the early detection of breast cancer.	<b>A\$342m</b>	A\$1.37	NZ\$16.5m	NZ\$20.8m loss	US\$750m
 <b>Genetic Signatures</b>	GSS.ASX	Specialist molecular diagnostics (MDx) for the routine detection of infectious diseases. High volume and rapid tests. COVID-19 Focus	<b>A\$328m</b>	A\$2.30	A\$4.9m	A\$3.5m loss	US\$8.4Bn
 <b>Atomo Diagnostics</b>	AT1.ASX	Disposable rapid tests for COVID-19 and HIV.	<b>A\$224m</b>	A\$0.40	A\$0.54m	A\$5.9m loss	US\$4.57Bn
 <b>Proteomics International Laboratories</b>	PIQ.ASX	Predictive DKD blood test which identifies and measures panel of novel protein biomarkers. Simple, cost effective, mass market blood test.	<b>A\$55.6m</b>	A\$0.605	A\$1.5m	A\$2.1m loss	US\$5.4Bn



# BOARD & MANAGEMENT

DIRECTORS HOLD  
25%



**Terry Sweet** FAICD, Chairman

Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Heartlink Ltd, and Scientific Services Ltd.



**Richard Lipscombe** PhD (London), MA (Oxon), Founder & Managing Director

Successfully managed the Company since listing in April 2015. 30 years experience in research and development globally in academic and commercial entities. Technical expertise in chemistry, immunology, & biomarker discovery.



**Roger Moore** R (Denmark), BPharm (U.Syd), Non-Executive Director

International pharmaceutical industry experience spanning 40 years, including almost 30 years as President of Novo Nordisk Japan. From 2000, he was appointed Novo Nordisk's Senior Vice President, Japan & Oceania Region. He has also served as a member of the Senior Management Board, Novo Nordisk A/S.



**Paul House** GAICD, BCommerce (UWA), Non-Executive Director

Over 25 years with multi-national corporations, CEO of Imdex (ASX:IMD), recently serving as MD of SGS India for 8 years. Previously held CFO and COO roles, and was Senior Manager at a leading global management consultancy firm.



**Chuck Morrison** BSc (Boston), MBA (Boston), Business Development

Over 35 years in life sciences, biotechnology, and diagnostic industries including DuPont and PerkinElmer.

# CONTACT



ASX:PIQ

## Richard Lipscombe

Managing Director

T: +61 8 9389 1992

E: [r.lipscombe@proteomicsinternational.com](mailto:r.lipscombe@proteomicsinternational.com)

[www.proteomicsinternational.com](http://www.proteomicsinternational.com)


## Dirk van Dissel

Corporate Advisor & Investor Relations

Candour Advisory

T: +61 408 326 367

E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)



**Proteomics International**

LABORATORIES LTD

**ASX:PIQ**